Bivalent aptamers deliver the punch.
Aptamers, sometimes termed "chemical antibodies," have been engineered into multimerized versions for therapeutic application. The groups of Gilboa and Sullenger now report the development of a bivalent aptamer-molecular device as a receptor agonist that has the same functional properties, but stronger avidity than a corresponding antibody.